In addition, puerarin promotes cell proliferation by upregulating Bcl-xL expression, promoting osteoblast proliferation and differentiated material through activation of MEK/ERK and PI3K/Akt pathways (Wang et al., 2013), and also inhibits osteoclastogenesis by reducing the pathway in which MCP-1 prevents migration of osteoclast precursor cells (OCPs) (Lin et al., 2020) and is expected to be a drug to prevent or delay osteoporosis. Here, AKT1 is linked to osteoporosis.